Chaoting Zhang#, Ting Liu#, Shance Li, Xia Teng, Yuge Zhu, Guanyu Zhang, Huimin Xie, Kang Sun, Jiaxin Tu, Wenjun Yang*, Zheming Lu* Membrane-bound IL-7 immobilized by the CD8 transmembrane region improves efficacy of CD19 CAR-T cell therapy,Molecular Cancer,(2024) 23:236

Zhang Chaoting, Li Shance,Shen Luyan，Teng Xia，Xiao Yefei，Yang Wenjun，Lu Zheming，Single cell sequencing of?tumour infltrating T cells efciently identifes tumour?specifc T cell receptors based on?the T cell activation score.,Cancer Immunol Immunother. 2024,73:123

Li S, Zhang C, Shen L, Teng X, Xiao Y, Yu B*, Lu Z*. TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3ζ -engineered NK cells mediates antitumor effects.,Cancer Immunol Immunother.,2022 Aug 21

Chaoting Zhang#, Yizhe Sun#, Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Nan Wu*, Zheming Lu*. Autophagic flux restoration enhances the antitumour efficacy of tumour infiltrating lymphocytes,Journal for ImmunoTherapy of Cancer，2022,10(10):e004868

Chaoting Zhang#, Yizhe Sun#, Shance Li, Luyan Shen, Xia Teng, Yefei Xiao, Ping Zhou*, Zheming Lu* Autophagic flux restoration of senescent T cells improves antitumor activity of TCR-engineered T cells.,Clin Transl Immunology. 2022,11(9):e1419

Cui L, Zhang C, Ding H, Feng D, Huang H, Lu Z*, Liu B*.Clonal Distribution and Intratumor Heterogeneity of the TCR Repertoire in Papillary Thyroid Cancer With or Without Coexistent Hashimoto's Thyroiditis.,Front Immunol.,2022 Jun 3

Shen Luyan, Xiao Yefei, Tian Jiahe, Lu Zheming*. Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy.,Cancer Lett.,2022 Mar 31;529:139-152.

Shen Luyan, Xiao Yefei, Zhang Chaoting, Li Shance, Teng Xia, Cui Likun, Liu Ting, Wu Nan*, Lu Zheming. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity.,Cancer Lett.,2022 Jul 10;538:215710.

Chaoting Zhang#, Qin Tan#, Shance Li#, Luyan Shen, Jingtao Zhang, Ying Liu, Wenjun Yang*, Zheming Lu*,Journal for Immunotherapy of Cancer,2021，9(7):e002516

Hui Liu#, Wen Lei #, Chaoting Zhang#, Chunmei Yang , Juying Wei , Qunyi Guo , Xiaojun Guo , Zhilu Chen , Ying Lu, Ken H Young*, Zheming Lu* , Wenbin Qian*. CD19-Specific CAR-T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor is Effective in Patients with PD-L1 Positive B-Cell Lymphoma,Clinical Cancer Research,2021,27(2):473-484.

Liang Yun#, Liu Hui#, Lu Zheming#, Lei Wen, Zhang Chaoting, Li Ping, Liang Aibin*, Young Ken H*, Qian Wenbin* CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies,J Hematol Oncol.,2021;14(1):26

Chaoting Zhang#, Heyilimu Palashati#, Zhuona Rong, Ningjing Lin, Luyan Shen, Ying Liu, Shance Li, Bentong Yu*, Wenjun Yang*, Zheming Lu* Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell malignancies,Molecular Cancer,2020，19(1):162

张超亭，陆哲明* :个体化肿瘤特异TCR的筛选策略,中国肿瘤生物治疗杂志,2021, Vol. 28,863-868

肿瘤个体化免疫治疗，包括CAR-T、TCR-T、Cancer Vaccine等

一种同时表达靶向CD19和CD20的CAR与PD1-CD28嵌合受体的慢病毒载体, 发明专利, 第1完成人, 国家知识产权局, 中国, 2020.7

靶向TRBC1 CAR-T细胞的制备方法与应用, 发明专利, 第1完成人, 国家知识产权局, 中国, 2020.6

一种筛选肿瘤特异TCR的方法, 发明专利, 第1完成人, 国家知识产权局, 中国, 2022.6

新型及通用型基因修饰 CAR 免疫细胞治疗淋巴细胞恶性疾病新技术及临床研究, 参加者, 2024.1.1～2028.12.31, 国家科技重大专项

CD19&PD1/CD28CAR-T 细胞治疗复发/难治B 细胞淋巴瘤患者的扩展性临床研究, 课题负责人, 2022.1.1～2024.12.31, 2022 年度首都卫生发展科研专项重点攻关项目

高效获得抗肿瘤TCR及其功能研究, 课题负责人, 2020.1.1～2023.12.31, 国家自然科学基金

抗肿瘤TCR的克隆及在食管鳞癌过继细胞治疗中的临床前研究, 课题负责人, 2017.1.1～2020.12.31, 北京市自然科学基金/7171001

免疫图谱动态检测预测肝癌Nivolumab治疗效果, 课题负责人, 2017.2.1～2020.8.31, 北京市科委“首都临床特色应用研究”专项/Z171100001017136

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式	操作
2025	肿瘤学	硕士	科学学位	肿瘤免疫治疗	全国统考